This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Xeljanz®(tofacitinib citrate) Prescribing information and Inflectra®(infliximab) Prescribing information. Adverse event reporting can be found at the bottom of the page.
In the past decade there have been major advances in investigations, pharmacological, non-pharmacological and surgical interventions for patients with IBD. This has allowed patients' treatment regime to be personalized to include medication, lifestyle changes, and possibly surgery.
The goal is to minimize the impact of UC on a patient's daily life, prevent disease progression, and enhance overall well-being. Collaborating closely with healthcare providers and following a comprehensive treatment approach can greatly support patients in effectively managing UC and achieving the best possible outcomes.
Ulcerative colitis and Crohn’s disease are the principal forms of inflammatory bowel disease. Both represent chronic inflammation of the gastrointestinal tract, which displays heterogeneity in inflammatory and symptomatic burden between patients and within individuals over time. Optimal management relies on understanding and tailoring evidence-based interventions by clinicians in partnership with patients.
This guideline for management of inflammatory bowel disease in adults over 16 years of age was developed by Stakeholders representing UK physicians (British Society of Gastroenterology), surgeons (Association of Coloproctology of Great Britain and Ireland), specialist nurses (Royal College of Nursing), paediatricians (British Society of Paediatric Gastroenterology, Hepatology and Nutrition), dieticians (British Dietetic Association), Radiologists (British Society of Gastrointestinal and Abdominal Radiology), general practitioners (Primary Care Society for Gastroenterology) and patients (Crohn’s and Colitis UK). A systematic review of 88247 publications and a Delphi consensus process involving 81 multidisciplinary clinicians and patients was undertaken to develop 168 evidence and expert opinion-based recommendations for pharmacological and surgical interventions, as well as optimal service delivery in the management of both ulcerative colitis and Crohn’s disease.1
View the full guidance here.
This guideline covers managing ulcerative colitis in children, young people and adults. It aims to help professionals to provide consistent high-quality care and it highlights the importance of advice and support for people with ulcerative colitis.
NICE has also produced a guideline on colonoscopic surveillance for adults with ulcerative colitis, Crohn's disease or adenomas.
This guideline includes new recommendations on inducing remission in mild-to-moderate ulcerative colitis. These supplement the existing recommendations on:
This guideline contains updated treatment targets for IBD were developed during the Selecting Therapeutic Targets in Inflammatory Bowel Disease II (STRIDE-II) initiative in 2021. The aim was to provide contemporary consensus recommendations for use in clinical practice.
Consensus recommendations were drafted and modified based on a systematic literature review and iterative surveys of 89 IOIBD members Consensus was reached if > 75% of participants scored a recommendation between 7 and 10 on a 10-point rating scale (1, do not agree at all; 10, agree completely).
View Complete STRIDE Guidelines Here
Overview: Ulcerative colitis: Management: Guidance (no date) NICE. Available at: https://www.nice.org.uk/guidance/ng130 (Accessed: 25 May 2023).
Click below to view the Immuno-navigator tool. An interactive tool to help you manage discussions with your patients .
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search
for MHRA Yellow Card in Google Play or Apple App Store
Adverse events should also be reported to Pfizer Medical Information on 01304 616161
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc
This website is brought to you by Pfizer Limited, a company registered in England
and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ
Copyright © 2023 Pfizer Limited. All rights reserved.
VAT registration number GB201048427
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-3863. November 2021